Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications use oral corticosteroids risk acute myocardial infarction
… effects is an important part of evaluating the benefit-risk balance of their products. However, primary efficacy … carefully conducted, it is a scientifically sound way to use existing studies to help understand long-term treatment …
… and rituximab increased to a peak of 31% in 2015, but its use had declined sharply by early 2016. Similarly, other … declined during the study period. In contrast, the use of a first-in-class Bruton’s tyrosine kinase inhibitor, … ibrutinib, increased sharply to 25.8% by early 2016. Its use increased among both younger patients and those over age …
… for this recorded 30-minute case-study workshop on the use of causal inference methods for real-world evidence. … Access and Outcomes Strategy Pharmacoepidemiology and Risk Management Biostatistics Real-World Evidence …
… Prevalence of underlying conditions associated with higher risk for severe RSV, influenza, or COVID-19 in adults in the …
… Medicaid data could be a good option for research on the use, effectiveness, and safety of childhood vaccines due to …
Knowledgebase - ICER Evaluations Image Image Image Knowledgebase KB Image Image KB …
… Like database studies , retrospective chart reviews also use real world data to help you better understand drivers …
IPECAD Cross Comparison Challenge on Cost-Effectiveness Models in Alz Disease and Related Dementias William L Herring, PhD Executive Director, Health Economics Transcript As disease-modifying therapies for Alzheimer’s disease, or AD, enter the market, …
… EDIB principles to the collection, interpretation, and use of patient preference information can support more … principles of EDIB to the collection, interpretation, and use of patient preference information in patient-focused drug … the perspectives of a diverse group. And third, use inclusive language in data collection tools and medical …
… of task. These include, but are not limited to: The use of regulatory flexibilities and supplementary data (e.g., …